REFERENCES

I. Mannhardt, K. Breckwoldt, D. Letuffe-Brenière, S. Schaaf, H. Schulz, C. Neuber, A. Benzin, T. Werner, A. Eder, T. Schulze, B. Klampe, T. Christ, M.N. Hirt, N. Huebner, T. Moretti, Alessandra Eschenhagen, A. Hansen, Human engineered heart tissue – analysis of contractile force, Stem Cell Reports (2016). http://dx.doi.org/10.1016/j.stemcr.2016.04.011.

A. Stoehr, M.N. Hirt, A. Hansen, M. Seiffert, L. Conradi, J. Uebeler, F.P. Limbourg, T. Eschenhagen, Spontaneous Formation of Extensive Vessel-Like Structures in Murine Engineered Heart Tissue., Tissue Eng. Part A. 22 (2016) 326–35. doi:10.1089/ten.TEA.2015.0242.

J. Stenzig, M.N. Hirt, A. Löser, L.M. Bartholdt, J.-T. Hensel, T.R. Werner, M. Riemenschneider, D. Indenbirken, T. Guenther, C. Müller, N. Hübner, M. Stoll, T. Eschenhagen, DNA methylation in an engineered heart tissue model of cardiac hypertrophy: common signatures and effects of DNA methylation inhibitors, Basic Res. Cardiol. 111 (2016) 9. doi:10.1007/s00395-015-0528-z.

J. Fiedler, K. Breckwoldt, C.W. Remmele, D. Hartmann, M. Dittrich, A. Pfanne, A. Just, K. Xiao, M. Kunz, T. Müller, A. Hansen, R. Geffers, T. Dandekar, T. Eschenhagen, T. Thum, Development of Long Noncoding RNA-Based Strategies to Modulate Tissue Vascularization., J. Am. Coll. Cardiol. 66 (2015) 2005–15. doi:10.1016/j.jacc.2015.07.081.

P.J.M. Wijnker, F.W. Friedrich, A. Dutsch, S. Reischmann, A. Eder, I. Mannhardt, G. Mearini, T. Eschenhagen, J. van der Velden, L. Carrier, Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue, J. Mol. Cell. Cardiol. 97 (2016) 82–92. doi:10.1016/j.yjmcc.2016.03.003.

A. Görbe, A. Eder, Z. V Varga, J. Pálóczi, A. Hansen, P. Ferdinandy, T. Eschenhagen, Protection by the NO-Donor SNAP and BNP against Hypoxia/Reoxygenation in Rat Engineered Heart Tissue., PLoS One. 10 (2015) e0132186. doi:10.1371/journal.pone.0132186.

A. Eder, I. Vollert, A. Hansen, T. Eschenhagen, Human engineered heart tissue as a model system for drug testing, Adv. Drug Deliv. Rev. (2015). doi:10.1016/j.addr.2015.05.010.

L. Conradi, S. Schmidt, E. Neofytou, T. Deuse, L. Peters, A. Eder, X. Hua, A. Hansen, R.C. Robbins, R.E. Beygui, H. Reichenspurner, T. Eschenhagen, S. Schrepfer, Immunobiology of fibrin-based engineered heart tissue., Stem Cells Transl. Med. 4 (2015) 625–31. doi:10.5966/sctm.2013-0202.

M.N. Hirt, T. Werner, D. Indenbirken, M. Alawi, P. Demin, A. Kunze, J. Stenzig, J. Starbatty, A. Hansen, J. Fiedler, T. Thum, T. Eschenhagen, Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology, J. Mol. Cell. Cardiol. 81 (2015) 1–9. doi:10.1016/j.yjmcc.2015.01.008.

I. Vollert, A. Eder, A. Hansen, T. Eschenhagen, Engineering Cardiovascular Regeneration, Curr. Stem Cell Reports. (2015). doi:10.1007/s40778-015-0010-8.

A. Eder, A. Hansen, J. Uebeler, T. Schulze, C. Neuber, S. Schaaf, L. Yuan, T. Christ, M. a. Vos, T. Eschenhagen, Effects of proarrhythmic drugs on relaxation time and beating pattern in rat engineered heart tissue, Basic Res. Cardiol. 109 (2014). doi:10.1007/s00395-014-0436-7.

S. Schaaf, A. Eder, I. Vollert, A. Stöhr, A. Hansen, T. Eschenhagen, Generation of strip-format fibrin-based engineered heart tissue (EHT)., Methods Mol. Biol. 1181 (2014) 121–9. doi:10.1007/978-1-4939-1047-2_11.

M.N. Hirt, J. Boeddinghaus, A. Mitchell, S. Schaaf, C. Börnchen, C. Müller, H. Schulz, N. Hubner, J. Stenzig, A. Stoehr, C. Neuber, A. Eder, P.K. Luther, A. Hansen, T. Eschenhagen, Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation., J. Mol. Cell. Cardiol. 74C (2014) 151–161. doi:10.1016/j.yjmcc.2014.05.009.

C. Neuber, J. Uebeler, T. Schulze, H. Sotoud, A. El-Armouche, T. Eschenhagen, Guanabenz interferes with ER stress and exerts protective effects in cardiac myocytes., PLoS One. 9 (2014) e98893. doi:10.1371/journal.pone.0098893.

A. Stoehr, C. Neuber, C. Baldauf, I. Vollert, F.W. Friedrich, F. Flenner, L. Carrier, A. Eder, S. Schaaf, M.N. Hirt, B. Aksehirlioglu, C.W. Tong, A. Moretti, T. Eschenhagen, A. Hansen, Automated analysis of contractile force and Ca2+ transients in engineered heart tissue., Am. J. Physiol. Heart Circ. Physiol. 306 (2014) H1353–63. doi:10.1152/ajpheart.00705.2013.

M.N. Hirt, A. Hansen, T. Eschenhagen, Cardiac tissue engineering: state of the art., Circ. Res. 114 (2014) 354–67. doi:10.1161/CIRCRESAHA.114.300522.

C. Neuber, O.J. Müller, F.C. Hansen, A. Eder, A. Witten, F. Rühle, M. Stoll, H.A. Katus, T. Eschenhagen, A. El-Armouche, Paradoxical effects on force generation after efficient β1-adrenoceptor knockdown in reconstituted heart tissue., J. Pharmacol. Exp. Ther. 349 (2014) 39–46. doi:10.1124/jpet.113.210898.

I. Vollert, M. Seiffert, J. Bachmair, M. Sander, A. Eder, L. Conradi, A. Vogelsang, T. Schulze, J. Uebeler, W. Holnthoner, H. Redl, H. Reichenspurner, A. Hansen, T. Eschenhagen, In vitro perfusion of engineered heart tissue through endothelialized channels., Tissue Eng. Part A. 20 (2014) 854–63. doi:10.1089/ten.TEA.2013.0214.

J. Fiedler, A. Stöhr, S.K. Gupta, D. Hartmann, A. Holzmann, A. Just, A. Hansen, D. Hilfiker-Kleiner, T. Eschenhagen, T. Thum, Functional microRNA library screening identifies the hypoxamir miR-24 as a potent regulator of smooth muscle cell proliferation and vascularization., Antioxid. Redox Signal. 21 (2014) 1167–76. doi:10.1089/ars.2013.5418.

A. Stöhr, F.W. Friedrich, F. Flenner, B. Geertz, A. Eder, S. Schaaf, M.N. Hirt, J. Uebeler, S. Schlossarek, L. Carrier, A. Hansen, T. Eschenhagen, Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice., J. Mol. Cell. Cardiol. (2013). doi:10.1016/j.yjmcc.2013.07.011.

M.-E. Cattin, A.T. Bertrand, S. Schlossarek, M.-C. Le Bihan, S. Skov Jensen, C. Neuber, C. Crocini, S. Maron, J. Lainé, N. Mougenot, S. Varnous, Y. Fromes, A. Hansen, T. Eschenhagen, V. Decostre, L. Carrier, G. Bonne, Heterozygous LmnadelK32 mice develop dilated cardiomyopathy through a combined pathomechanism of haploinsufficiency and peptide toxicity., Hum. Mol. Genet. 22 (2013) 3152–64. doi:10.1093/hmg/ddt172.

C. Crocini, T. Arimura, S. Reischmann, A. Eder, I. Braren, A. Hansen, T. Eschenhagen, A. Kimura, L. Carrier, Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue, Basic Res. Cardiol. 108 (2013). doi:10.1007/s00395-013-0349-x.

M.N. Hirt, N.A. Sörensen, L.M. Bartholdt, J. Boeddinghaus, S. Schaaf, A. Eder, I. Vollert, A. Stöhr, T. Schulze, A. Witten, M. Stoll, A. Hansen, T. Eschenhagen, Increased afterload induces pathological cardiac hypertrophy: a new in vitro model., Basic Res. Cardiol. 107 (2012) 307–323. doi:10.1007/s00395-012-0307-z.

T. Eschenhagen, A. Eder, I. Vollert, A. Hansen, Physiological aspects of cardiac tissue engineering., Am. J. Physiol. Heart Circ. Physiol. 303 (2012) H133–43. doi:10.1152/ajpheart.00007.2012.

S. Chiron, C. Tomczak, A. Duperray, J. Lainé, G. Bonne, A. Eder, A. Hansen, T. Eschenhagen, C. Verdier, C. Coirault, Complex interactions between human myoblasts and the surrounding 3D fibrin-based matrix., PLoS One. 7 (2012) e36173. doi:10.1371/journal.pone.0036173.

F.W. Friedrich, B.R. Wilding, S. Reischmann, C. Crocini, P. Lang, P. Charron, O.J. Müller, M.J. Mcgrath, I. Vollert, A. Hansen, W.A. Linke, C. Hengstenberg, G. Bonne, S. Morner, T. Wichter, H. Madeira, E. Arbustini, T. Eschenhagen, C.A. Mitchell, R. Isnard, L. Carrier, Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy., Hum. Mol. Genet. 21 (2012) 3237–54. doi:10.1093/hmg/dds157.

S. Schaaf, A. Shibamiya, M. Mewe, A. Eder, A. Stöhr, M.N. Hirt, T. Rau, W.-H. Zimmermann, L. Conradi, T. Eschenhagen, A. Hansen, Human Engineered Heart Tissue as a Versatile Tool in Basic Research and Preclinical Toxicology, PLoS One. 6 (2011) e26397. doi:10.1371/journal.pone.0026397.

L. Conradi, C. Pahrmann, S. Schmidt, T. Deuse, A. Hansen, A. Eder, H. Reichenspurner, R.C. Robbins, T. Eschenhagen, S. Schrepfer, Bioluminescence imaging for assessment of immune responses following implantation of engineered heart tissue (EHT)., J. Vis. Exp. (2011).

R.D. Will, M. Eden, S. Just, A. Hansen, A. Eder, D. Frank, C. Kuhn, T.S. Seeger, U. Oehl, S. Wiemann, B. Korn, M. Koegl, W. Rottbauer, T. Eschenhagen, H.A. Katus, N. Frey, Myomasp/LRRC39, a heart- and muscle-specific protein, is a novel component of the sarcomeric M-band and is involved in stretch sensing., Circ. Res. 107 (2010) 1253–64. doi:10.1161/CIRCRESAHA.110.222372.

A. Hansen, A. Eder, M. Bönstrup, M. Flato, M. Mewe, S. Schaaf, B. Aksehirlioglu, A.P. Schwoerer, J. Uebeler, T. Eschenhagen, Development of a drug screening platform based on engineered heart tissue., Circ. Res. 107 (2010) 35–44. doi:10.1161/CIRCRESAHA.109.211458.